Literature DB >> 27048788

The importance of sexual function in men with spinal cord injuries.

Jason R Kovac1, Larry I Lipshultz.   

Abstract

Entities:  

Mesh:

Year:  2016        PMID: 27048788      PMCID: PMC4854087          DOI: 10.4103/1008-682X.179247

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


× No keyword cloud information.
Spinal cord injuries (SCIs) are often devastating to patients and their families. In those men young enough to consider families and unfortunate enough to be unable to ejaculate, multiple options exist. The attached manuscript by Dr. Ibrahim et al.1 contains a detailed outline of a multitude of techniques available to the Andrologist to both evoke ejaculation and harvest sperm from these patients. The authors, pioneers in the field of male fertility research for SCI patients, detail very high success rates for penile vibratory stimulation (86% success if above T10, 15% if below) and electroejaculation (91.9% success). It is important when assessing male fertility patients with SCI that a detailed sexual history is obtained with a specific focus on whether patients can obtain erections. Information regarding the medications and interventions previously utilized is also beneficial. Some patients have simply never been presented with any options to treat their erectile dysfunction (ED). As such, identification and correction of this simple oversight could promote fertility without the need for any additional interventions. Sildenafil has been proven to be a valuable and safe medication in the management of ED in male SCI patients that is simple to administer and monitor.2 Absence of both psychogenic and reflexive erections will preclude successful treatments with PDE5 inhibitors.2 In those patients, intracavernosal injection (ICI) provides a reliable and safe alternative.3 Caution is required since men with SCI typically require significantly lower doses of ICI than healthy men, and the hypotensive effects of the medications need to be considered. Other options include intra-urethral prostaglandin, vacuum erection devices and implantable penile prostheses.4 A second issue that should also be discussed with male SCI patients is libido. While research has suggested that the SCI affects sexual behavior with regards to performance and body sensitivity,5 chronic pain treated with opiods6 may also affect libido through a testosterone ablative mechanism.7 As such, following confirmation of low levels of libido on history, an analysis of a patients serum hormones including testosterone could prove insightful. Restoration of these endocrine deficiencies may then restore the desire for sexual functioning.
  7 in total

1.  Treatments for chronic pain in persons with spinal cord injury: A survey study.

Authors:  Diana D Cardenas; Mark P Jensen
Journal:  J Spinal Cord Med       Date:  2006       Impact factor: 1.985

2.  Sildenafil in the treatment of sexual dysfunction in spinal cord-injured male patients.

Authors:  D M Schmid; B Schurch; D Hauri
Journal:  Eur Urol       Date:  2000-08       Impact factor: 20.096

Review 3.  Opioid-induced androgen deficiency (OPIAD).

Authors:  Howard S Smith; Jennifer A Elliott
Journal:  Pain Physician       Date:  2012-07       Impact factor: 4.965

Review 4.  Treatment of erectile dysfunction following spinal cord injury.

Authors:  Todd A Linsenmeyer
Journal:  Curr Urol Rep       Date:  2009-11       Impact factor: 3.092

5.  Intracavernous papaverine for impotence in spinal cord injured patients.

Authors:  V K Kapoor; A S Chahal; S P Jyoti; Y J Mundkur; S V Kotwal; V K Mehta
Journal:  Paraplegia       Date:  1993-10

6.  Self-awareness of the male sexual response after spinal cord injury.

Authors:  Fernando Luiz Cardoso; Ana Carolina R Savall; Aline K Mendes
Journal:  Int J Rehabil Res       Date:  2009-12       Impact factor: 1.479

Review 7.  Advances in the management of infertility in men with spinal cord injury.

Authors:  Emad Ibrahim; Nancy L Brackett; Charles M Lynne
Journal:  Asian J Androl       Date:  2016 May-Jun       Impact factor: 3.285

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.